ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS
20 SEPTEMBER 2022 at 13.15 EEST
        

Change in Orion Group Executive Management Board as of 1 November 2022 – Juhani Kankaanpää appointed as Senior Vice President of Global Operations

Juhani Kankaanpää has been appointed as Senior Vice President, Global Operations, and member of the Executive Management Board of Orion Group as of 1 November 2022. Mr. Kankaanpää has been working in management positions at Orion since 2016 with responsibility for, among other things, developing operational activities, leading the controller team and leading the Orion Group's strategy process. He is currently responsible for the integration of Orion Animal Health and the acquired veterinary pharmaceutical company Inovet (VMD). Previously, he has held several operational management positions at Orkla, and has worked as a consultant at The Boston Consulting Group. Mr Kankaanpää holds a Master of Science in Technology (industrial engineering and management) degree.

“I am delighted that Juhani will lead Orion's operational activities. He has extensive experience in operations and in the different functions and the whole of Orion. I wish Juhani every success in his new role”, says SVP, Global Operations, Liisa Hurme who will start as Orion’s President and CEO on 1 November 2022.

“I am excited and grateful for this appointment, and I look forward to the new tasks ahead. I am familiar with Orion's operations from my previous roles and the staff there are highly competent. I look forward to working with them and developing Orion together”, says Juhani Kankaanpää.

Orion Corporation

                                                
Contact person:
Liisa Hurme, SVP, Global Operations, Orion’s President and CEO as of 1 November 2022
tel. +358 10 426 2874 

Contact person for media:
Terhi Ormio, Vice President, Communications
phone +358 50 966 4646, terhi.ormio@orion.fi

ANNEX: The CV of Juhani Kankaanpää

Juhani Kankaanpää

Born 1980

Education

Master of Science in Technology, Aalto University, 2006

Career

2022–        Director, Integration of Orion Animal Health and Inovet (VMD), Orion Corporation
2021–2022        Director, Strategy and Business Planning, Orion Corporation
2016–2021        Director, Operations Development, Orion Corporation
2013–2016        Project Leader, The Boston Consulting Group
2011–2013        Operations Director, Orkla Foods Finland
2010–2011        Plant Director, Felix Abba Oy (Orkla Group)
2009–2010        Plant Manager, Felix Abba Oy (Orkla Group)
2008–2009        Project Manager, Orkla Foods Fenno-Baltic Corporate Development
2006–2008        Consultant, BearingPoint consulting        

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are oncology and pain. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.